Revive Therapeutics Provides Update on FDA Type C Meeting for Clinical Study of Bucillamine to Treat Long COVID
Stock Information for Revive Therapeutics Ltd
Loading
Please wait while we load your information from QuoteMedia.
Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.